Financing News | SynBiome Finishes Angel Round of Financing with Tens of Millions of Yuan, with Investment Led by Heda Biomedicine Industrial Fund, Followed by Yael Capital and Voyong Fund

Good news of companies

➣➣➣ Recently, SynBiome Biotechnology Co., Ltd. (hereinafter referred to as SynBiome), a company settled in the Innovation Center, has completed an angel round of financing with tens of millions of yuan, with the investment led by Heda Biomedicine Industrial Fund, and followed by Yael Capital and Voyong Fund.

About SynBiome

 图片 101.png

Founded in June 2022, SynBiome is a biotechnology company co-established by a returnee young scientist and an executive of a venture capital institution. Through the integration of artificial intelligence and synthetic biology technology, the company is committed to building a data-driven microbiome engineering platform, developing functional microorganisms and bio-active substances to promote the health of crops, animals and human beings and providing innovative products and solutions for fields such as agriculture, carbon neutrality and big health.

The company’s founder and chief scientist Dr. Dai Lei, graduated from the Massachusetts Institute of Technology, who has long been working in the field of microbiomics and synthetic biology. In 2018, he returned to China to join the SIAT of Chinese Academy and serve as a doctoral supervisor and director of the Synthetic Microbiome Center. In 2019, he was honored as one of the “35 technology innovators under the age of 35” by the MIT Technology Review.

Mr. Chen Yin, co-founder and CEO of the company, graduated from Shanghai University of Finance and Economics. He is a senior practitioner in the domestic venture capital industry. He has rich experience in industrial investment and management in the fields of biomedicine and big health. After the completion of this round of financing, SynBiome has actively responded to the “upstairs and downstairs innovation and entrepreneurship complex” model pioneered by the SIAT, and has settled in the Shenzhen Industrial Innovation Center for Engineering Biology. Meanwhile, relying on the high-flux and automated experimental platform of “Shenzhen Synthetic Biology Infrastructure” co-built by the Chinese Academy of Sciences and the Shenzhen municipal government, the industrial transformation efficiency of the company’s scientific research and innovation has been greatly improved.

 图片 2.png

Figure | The exhibition hall of the Innovation Center

The long-term vision of the company is to create a new life with microorganisms. Other than promoting its existing pipelines at a faster pace, the company is also looking for more industrial and strategic partners to promote the application of microbiome engineering in various industries (such as pet protection, makeup and skincare, nutrition and healthcare), and transform more “knowledge” of cutting-edge science and technology into “application” to benefit the society.